English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  A large fraction of HLA class I ligands are proteasome-generated spliced peptides.

Liepe, J., Marino, F., Sidney, J., Jeko, A., Bunting, D. E., Sette, A., et al. (2016). A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science, 354(6310), 354-358. doi:10.1126/science.aaf4384.

Item is

Files

show Files
hide Files
:
2472947.pdf (Publisher version), 739KB
 
File Permalink:
-
Name:
2472947.pdf
Description:
-
OA-Status:
Visibility:
Restricted (UNKNOWN id 303; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Liepe, J.1, Author           
Marino, F., Author
Sidney, J., Author
Jeko, A., Author
Bunting, D. E., Author
Sette, A., Author
Kloetzel, P. M., Author
Stumpf, M.l P. H., Author
Heck, A. J. R., Author
Mishto, M., Author
Affiliations:
1Research Group of Quantitative and System Biology, MPI for Biophysical Chemistry, Max Planck Society, ou_2466694              

Content

show
hide
Free keywords: -
 Abstract: The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules that elicit CD8+ T cell responses. Reports of proteasome-generated spliced epitopes exist, but they have been regarded as rare events. Here, however, we show that the proteasome-generated spliced peptide pool accounts for one-third of the entire HLA class I immunopeptidome in terms of diversity and one-fourth in terms of abundance. This pool also represents a unique set of antigens, possessing particular and distinguishing features. We validated this observation using a range of complementary experimental and bioinformatics approaches, as well as multiple cell types. The widespread appearance and abundance of proteasome-catalyzed peptide splicing events has implications for immunobiology and autoimmunity theories and may provide a previously untapped source of epitopes for use in vaccines and cancer immunotherapy.

Details

show
hide
Language(s): eng - English
 Dates: 2016-10-21
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: DOI: 10.1126/science.aaf4384
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Science
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 354 (6310) Sequence Number: - Start / End Page: 354 - 358 Identifier: -